Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors
Hepatocellular carcinoma (HCC) is a major health concern worldwide, and its incidence is increasing steadily. To date, receptor tyrosine kinases (RTKs) are the most favored molecular targets for the treatment of HCC, followed by immune checkpoint regulators such as PD-1, PD-L1, and CTLA-4. With less...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-7737/11/4/585 |
| _version_ | 1797436810303897600 |
|---|---|
| author | Hyunjung Park Hyerin Park Jiyeon Baek Hyuk Moon Simon Weonsang Ro |
| author_facet | Hyunjung Park Hyerin Park Jiyeon Baek Hyuk Moon Simon Weonsang Ro |
| author_sort | Hyunjung Park |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) is a major health concern worldwide, and its incidence is increasing steadily. To date, receptor tyrosine kinases (RTKs) are the most favored molecular targets for the treatment of HCC, followed by immune checkpoint regulators such as PD-1, PD-L1, and CTLA-4. With less than desirable clinical outcomes from RTK inhibitors as well as immune checkpoint inhibitors (ICI) so far, novel molecular target therapies have been proposed for HCC. In this review, we will introduce diverse molecular signaling pathways that are aberrantly activated in HCC, focusing on YAP/TAZ, Hedgehog, and Wnt/β-catenin signaling pathways, and discuss potential therapeutic strategies targeting the signaling pathways in HCC. |
| first_indexed | 2024-03-09T11:07:59Z |
| format | Article |
| id | doaj.art-4668d126bd504ce7be9756c763704e77 |
| institution | Directory Open Access Journal |
| issn | 2079-7737 |
| language | English |
| last_indexed | 2024-03-09T11:07:59Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biology |
| spelling | doaj.art-4668d126bd504ce7be9756c763704e772023-12-01T00:51:56ZengMDPI AGBiology2079-77372022-04-0111458510.3390/biology11040585Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint InhibitorsHyunjung Park0Hyerin Park1Jiyeon Baek2Hyuk Moon3Simon Weonsang Ro4Department of Genetics and Biotechnology, College of Life Sciences, Kyung Hee University, Yongin-si 17104, KoreaDepartment of Genetics and Biotechnology, College of Life Sciences, Kyung Hee University, Yongin-si 17104, KoreaDepartment of Genetics and Biotechnology, College of Life Sciences, Kyung Hee University, Yongin-si 17104, KoreaDepartment of Genetics and Biotechnology, College of Life Sciences, Kyung Hee University, Yongin-si 17104, KoreaDepartment of Genetics and Biotechnology, College of Life Sciences, Kyung Hee University, Yongin-si 17104, KoreaHepatocellular carcinoma (HCC) is a major health concern worldwide, and its incidence is increasing steadily. To date, receptor tyrosine kinases (RTKs) are the most favored molecular targets for the treatment of HCC, followed by immune checkpoint regulators such as PD-1, PD-L1, and CTLA-4. With less than desirable clinical outcomes from RTK inhibitors as well as immune checkpoint inhibitors (ICI) so far, novel molecular target therapies have been proposed for HCC. In this review, we will introduce diverse molecular signaling pathways that are aberrantly activated in HCC, focusing on YAP/TAZ, Hedgehog, and Wnt/β-catenin signaling pathways, and discuss potential therapeutic strategies targeting the signaling pathways in HCC.https://www.mdpi.com/2079-7737/11/4/585hepatocellular carcinomatarget therapyYAP/TAZHedgehogWnt/β-cateninanimal models |
| spellingShingle | Hyunjung Park Hyerin Park Jiyeon Baek Hyuk Moon Simon Weonsang Ro Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors Biology hepatocellular carcinoma target therapy YAP/TAZ Hedgehog Wnt/β-catenin animal models |
| title | Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors |
| title_full | Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors |
| title_fullStr | Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors |
| title_full_unstemmed | Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors |
| title_short | Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors |
| title_sort | target therapy for hepatocellular carcinoma beyond receptor tyrosine kinase inhibitors and immune checkpoint inhibitors |
| topic | hepatocellular carcinoma target therapy YAP/TAZ Hedgehog Wnt/β-catenin animal models |
| url | https://www.mdpi.com/2079-7737/11/4/585 |
| work_keys_str_mv | AT hyunjungpark targettherapyforhepatocellularcarcinomabeyondreceptortyrosinekinaseinhibitorsandimmunecheckpointinhibitors AT hyerinpark targettherapyforhepatocellularcarcinomabeyondreceptortyrosinekinaseinhibitorsandimmunecheckpointinhibitors AT jiyeonbaek targettherapyforhepatocellularcarcinomabeyondreceptortyrosinekinaseinhibitorsandimmunecheckpointinhibitors AT hyukmoon targettherapyforhepatocellularcarcinomabeyondreceptortyrosinekinaseinhibitorsandimmunecheckpointinhibitors AT simonweonsangro targettherapyforhepatocellularcarcinomabeyondreceptortyrosinekinaseinhibitorsandimmunecheckpointinhibitors |